Evidence that tirzepatide protects against diabetes-related cardiac damages

Evidence that tirzepatide protects against diabetes-related cardiac damages

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE), their impact on heart failure (HF) remains unclear...

Full description

Bibliographic Details
Main Authors: Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Eduardo Sommella, Giuseppe Signoriello, Fabiola Olivieri, Michelangela Barbieri, Giuseppe Paolisso
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Cardiovascular Diabetology
Subjects:
Tirzepatide
Heart failure
AC16 cell line
High glucose
GIP receptor
GLP-1 receptor.
Online Access:https://doi.org/10.1186/s12933-024-02203-4

Internet

https://doi.org/10.1186/s12933-024-02203-4

Similar Items